170808 ⎘
Detection or diagnosis of diseases; Hepato-biliairy disorders other than hepatitis Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Compositions and methods for treating liver injury
#302Uses of GLI1 in detecting tissue fibrosis
#303METHOD FOR MEASURING A BIOLOGICAL VALUE OF A LIVER
#304Compositions, methods, and devices for treating disease
#305Diagnosis of chronic liver diseases
#306Systems and methods for electrochemical ketone detection and measurement
#307Diagnosis of liver pathology through assessment of protein glycosylation
#308Methods for diagnosis and intervention of hepatic disorders
#309Differential diagnosis of liver disease
#310METHOD AND A KIT FOR THE DIAGNOSIS OF HEPATIC DISEASE UTILIZING THE SULFYDRYL-OXIDIZING PROPERTY OF SERUM
#311Determination of the unbound free fatty acid profiles in biological and industrial specimens
#312Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method
#313Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
#314Biomarkers related to organ function
#315Combined biomarker measurement of fibrosis
#316Kit and method for diagnosis, prognosis or monitoring of liver disease through measurement of amount of AST
#317Acetaminophen as a Marker of Hepatic Disorders
#318CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS
#319BIOMARKERS ASSOCIATED WITH DIABETES AND FIBROSIS
#320Method for investigation of liver damage type
#321CHI3L1 FOR THE DETECTION AND TREATMENT OF NONALCOHOLIC STEATOHEPATITIS
#322Vitamin D receptor/SMAD genomic circuit gates fibrotic response
#323Fibrosis biomarker assay
#324Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment
#325CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS
#326Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation
#327Methods of identifying compounds for the treatment of fibrosis by using S1PR5
#328PIIINP neo-epitope assay
#329Method for measuring bile salt export transport and/or formation activity
#330Lipopeptides for use in treating liver diseases and cardiovascular diseases
#331Application of N-terminomics to NETosis in inflammation
#332Method for detecting bilirubin using a fluorescent protein
#333Biomarkers for fatty liver disease and methods using the same
#334BIOMARKERS OF ACUTE LIVER INJURY
#335Glucagon/GLP-1 receptor co-agonists
#336Methods and devices for determining a disease state
#337Biomarkers for differentiating between non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD)
#338Methods of therapeutic monitoring of nitrogen scavenging drugs
#339Biomarkers for liver fibrosis
#340Biomarkers for the identification of liver damage
#341Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
#342Immunoassay of S-adenosylmethionine in personalized medicine and health or cancer evaluation
#343Detecting and Treating Liver Damage
#344Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method
#345Biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease by using such biomarkers
#346Methods and compositions for diagnosis of inflammatory liver disease
#347Cholyl-L-Lysyl-Fluorescein Assay
#348Method for providing reliable non-invasive diagnostic tests
#349Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
#350Cancer Diagnosis by Measuring Polyisoprenylated Methylated Protein Methyl Esterase Activity
#351Method for diagnosing acute alcoholic hepatitis
#352Anti-αβantibodies
#353Method for predicting risk of exposure to interstitial fibrosis and tubular atrophy with clusterin
#354CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS
#355Prophylactic or therapeutic agent for hepatic diseases
#356METHOD OF PROGNOSIS
#357Antibodies and method for determining deletions in HBV pre-S region
#358METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS
#359Use of SAA1B/B homozygote in the prognosis and diagnosis of liver cirrhosis
#360MEANS AND METHODS FOR ASSESSING LIVER DISORDERS
#361METHOD FOR DETERMINING LIVER FAT AMOUNT AND METHOD FOR DIAGNOSING NAFLD
#362ADAM12 inhibitors and their use against inflammation-induced fibrosis
#363METHODS AND COMPOSITIONS FOR DETECTING AND TREATING INFLAMMATORY DISEASE
#364Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
#365Biomarkers for liver fibrosis
#366Anti-GP73 monoclonal antibodies and methods of obtaining the same
#367Immunoassay methods
#368Acute hepatic insufficiency depressant and method for evaluating drug efficacy thereof
#369Immunoassay methods
#370Glucagon/GLP-1 receptor co-agonists
#371Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
#372Method of evaluating fatty liver related disease, fatty liver related disease-evaluating apparatus, fatty liver related disease-evaluating method, fatty liver related disease-evaluating program product, fatty liver related disease-evaluating system, information communication terminal apparatus, and method of searching for prophylactic/ameliorating substance for fatty liver related disease
#373Biomarkers useful in liver fibrosis diagnosis
#374Method for diagnosing acute alcoholic hepatitis
#375Methods for diagnosis and intervention of hepatic disorders
#376Adiponectin receptor C-terminal fragments (CTF)-immunoglobulin
#377Breath test device and method
#378Cell division marker
#379Composition and method for the diagnosis and treatment of iron-related disorders
#380Treating renal and liver dysfunction with TLR4 antagonists
#381Combination of biomarkers for the detection and evaluation of hepatitis fibrosis
#382Novel biomarker for non-alcoholic fatty liver disease, and method for detecting non-alcoholic fatty liver disease by using the biomarker
#383Use of VAP-1 inhibitors for treating fibrotic conditions
#384Composition for diagnosing, treating, and preventing liver disease
#385Biomarkers for diagnosing liver disease
#386LIVER DISEASE MARKER, METHOD AND APPARATUS FOR MEASURING THE SAME, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION
#387Methods of therapeutic monitoring of nitrogen scavenging
#388FLC AS BIOMARKER
#389DETECTION AND MONITORING OF NONALCOHOLIC FATTY LIVER DISEASE
#390Treatment of fibrosis using microRNA 19b
#391Glucagon/GLP-1 receptor co-agonists
#392Glucagon/GLP-1 receptor co-agonists
#393Method for assessment of hepatic function and portal blood flow
#394METHOD CIRCUIT AND SYSTEM FOR DETECTING A CONNECTION REQUEST WHILE MAINTAINING A LOW POWER MODE
#395METHOD OF PROGNOSIS
#396ANTI-ALPHA V BETA 6 ANTIBODIES
#397Method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens
#398FIBROSIS INHIBITOR
#399COMPOSITIONS, METHODS, AND DEVICES FOR TREATING LIVER DISEASE
#400ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis
#401DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION
#402USE OF DRONEDARONE FOR THE PREPARATION OF A DRUG FOR USE IN THE MANAGEMENT OF THE RISK OF LIVER INJURY
#403Glycan markers as measure of disease state of hepatic diseases
#404Method for the differential diagnosis of non-alcoholic fatty liver disease based on a metabolomic profile
#405METHOED FOR DETECTING CIRCULATING CARTILAGE OLIGOMERIC MATRIX PROTEIN IN THE DIAGNOSIS AND MONITORING OF CIRRHOSIS
#406Method for measuring glycoprotein, method for examining liver disease, reagent for quantitative determination of glycoprotein, and glycan-marker glycoprotein as an index for clinical conditions of liver disease
#407METHODS AND COMPOSITIONS FOR DETECTING AND TREATING INFLAMMATORY DISEASE
#408DIAGNOSTIC METHODS FOR LIVER DISORDERS
#409DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS
#410Non-Invasive Method for Assessing Liver Fibrosis Progression
#411NON-INVASIVE IN VITRO METHOD FOR QUANTIFYING LIVER LESIONS
#412Anti-αβantibodies and uses thereof
#413Hepatic disease-evaluating apparatus, hepatic disease-evaluating method, hepatic disease-evaluating system, hepatic disease-evaluating program and recording medium
#414Measurement device and method for analyzing a sample gas by infrared absorption spectroscopy
#415UBIQUITIN PROTEASOME SYSTEM PROFILING FOR DIAGNOSIS OF CHRONIC LIVER DISEASE
#416DIFFERENTIATING BETWEEN FIBROSIS AND CIRRHOSIS
#417METHOD FOR ASSESSMENT OF SEVERITY OF LIVER CIRRHOSIS
#418Screening Method for Identifying Patients at Risk of Adverse Hepatologic Events
#419Detection and monitoring of liver damage
#420Progastrin and liver pathologies
#421Glucuronidated Acetaminophen as a Marker of Hepatic Disorders
#422Biomarkers and methods for determining disease progression in nonalcoholic steatohepatitis (NASH)
#423Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
#424SPECIFIC BINDING MEMBERS AGAINST SYNAPTOPHYSIN
#425Method for diagnosing liver toxicity with sex specific biomarkers
#426Detection and monitoring of liver damage
#427Biomarker for diagnosis of liver disease
#428Cell division marker
#429METHOD FOR DIAGNOSING LIVER FIBROSIS
#430MOLECULAR SIGNATURE FOR FIBROSIS AND ATROPHY
#431Methods related to liver enzyme induction as a predisposition for liver toxicity and diseases or disorders associated therewith
#432CHEMICAL MODULATION OF ELECTRONIC AND MAGNETIC PROPERTIES OF GRAPHENE
#433Keratin 8 mutations are risk factors for developing liver disease of multiple etiologies
#434METHOD OF DETERMINING ALANINE TRANSAMINASE (ALT) ACTIVITY BY 13C-MR DETECTION USING HYPERPOLARISED 13C-PYRUVATE
#435Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis
#436Methods of diagnosing non-alcoholic steatohepatitis (NASH)
#437Method for assaying bilirubin and assay instrument used in bilirubin assay
#438Serum Biomarkers for Diagnosing Liver Fibrosis and Method for Measuring the Same
#439Diagnosis of liver pathology through assesment of protein glycosylation
#440Use of FZC18-Containing Collagen 18 Polypeptides for the Treatment, Diagnosis and Outcome Prediction of Diseases
#441METHOD OF DIAGNOSTIC HEPARIC DISEASE BY SUGAR CHAIN ANALYSIS
#442Biomarkers for liver injury
#443METHOD AND REAGENTS FOR TREATING HEPATIC FIBROSIS AND INFLAMMATION
#444Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
#445Biomarkers For Fatty Liver Disease And Methods Using The Same
#446Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders
#447Biomarkers for liver diseases and method for using the same
#448Biomarkers for inflammation of the liver
#449MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF
#450COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
#451MIA-2 PROTEIN
#452Fibrosis biomarker assay
#453Histochemical and biomarker for liver fibrosis
#454Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease
#455FIBROSIS INHIBITOR
#456Use of β-2-microglobulin to assess glomerular alterations and damage in the kidney
#457BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS
#458Regulation of lipid droplet formation by modulation of FIT1 and FIT2 and uses thereof
#459METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OR STABILIZATION OF FIBROSIS
#460Methods for diagnosis and intervention of hepatic disorders
#461Methods for diagnosing and monitoring liver diseases
#462Methods of treatment using ammonia-scavenging drugs
#463Biomarkers for assessing liver function
#464Method to measure serum biomarkers for the diagnosis of liver fibrosis
#465Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation
#466Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
#467COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
#468USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS
#469Diagnosis of liver pathology through assessment of protein glycosylation
#470Methods for treating fibrosis using CRP antagonists
#471Anti-αβantibodies
#472In vitro method for the detection of early-stage liver damage
#473SERUM BIOMARKERS OF HEPATITIS B VIRUS INFECTED LIVER AND METHODS FOR DETECTION THEREOF
#474Method of diagnosing the presence and/or severity of a hepatic pathology in an individual and/or of monitoring the effectiveness of a treatment for one such pathology
#475Formation and rejuvenation of organs and alcohol damaged organ regeneration through stem cell nutrients
#476Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
#477Breath test device and method
#478Fibrosis Markers
#479METHOD FOR DETECTION, DETERMINATION OR PREDICTION OF HEPATIC DISORDER
#480METHOD FOR NON-INVASIVE EXAMINATION OF NON-ALCOHOLIC STEATOHEPATITIS BY QUANTIFICATION OF CYTOCHROME-c, AND TEST KIT
#481Human FGF-21 gene and gene expression products
#482Connective Tissue Growth Factor-4
#483DISEASE DIAGNOSIS BY PROFILING SERUM GLYCANS
#484Methods of diagnosing non-alcoholic steatohepatitis (NASH)
#485Anti-αβantibodies and uses thereof
#486Methods for diagnosis and intervention of hepatic disorders
#487Specific binding members against synaptophysin
#488Biomarkers for liver diseases and method for using the same
#489Methods and assays for detecting GP73-specific autoantibodies
#490Hepatic disease-evaluating apparatus, hepatic disease-evaluating method, hepatic disease-evaluating system, hepatic disease-evaluating program and recording medium
#491Compositions, methods, and devices for treating liver disease
#492Diagnos and Treatment of Fibrosis Related Pathology
#493Stabilized Ornithine Transcarbamylase and Immunoassay Method for Ornithine Transcarbamylase Using the Same
#494Pathological Animal Model For Non-Alcoholic Fatty Hepatitis
#495Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
#496Detection and monitoring of liver damage
#497Monitoring Agent for Seriousness of Hepatitis
#498Cellular predictive models for toxicities
#499Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
#500Human FGF-21 gene and gene expression products
#501Method and system for predicting liver fibrosis and related pathologies
#502Connective Tissue Growth Factor-4
#503Assay for phospholipidosis
#504Methods and compositions for treating disorders of the extracellular matrix
#505Biomarkers for liver fibrotic injury
#506METHOD FOR DIAGNOSING LIVER FIBROSIS
#507METHOD FOR DIAGNOSING LIVER FIBROSIS
#508Liver disease-related methods and systems
#509Cell division marker
#510Diagnostic kit for liver cirrhosis comprising an antibody specific for human protooncogenic protein
#511Human FGF-21 gene and gene expression products
#512Therapeutic, prophylactic and diagnostic agents
#513Diagnosis of liver pathology through assessment of protein glycosylation
#514Molecular hepatotoxicology modeling
#515Interleukin-8 homologous polypeptides and therapeutic uses thereof
#516Compositions and methods for inhibiting liver stellate cell growth
#517Glycosyl phosphatidyl inositol specific phospholipase D proteins and uses thereof
#518Biomarkers of liver injury
#519Methods for detecting TAFIa or TAFIai
#520Interleukin-8 homologous polypeptides and therapeutic uses thereof
#521Method for diagnosing liver diseases
#522Cell culture and method for screening for a compound useful in the treatment or prevention of hepatic cirrhosis
#523Methods of diagnosing liver fibrosis
#524Serum marker for measuring liver fibrosis
#525Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1
#526Anti-αβantibodies
#527Biomarkers for liver diseases and method for using the same
#528Marker for measuring liver cirrhosis
#529Serum biomarkers of hepatitis B virus infected liver and methods for detection thereof
#530Interleukin-8 homologous polypeptides and therapeutic uses thereof
#531Human FGF-21 gene and gene expression products
#532Method and composition for treating non-cirrhotic NASH
#533Liver disease
#534Biomarker for the prediction of primary non function of a liver graft
#535Methods for treating cholestatic liver fibrosis